Campbell W, Tilstone W, Lawson D, Hutton I, Lawrie T
Br J Clin Pharmacol. 2012; 3(6):1023-6.
PMID: 22216524
PMC: 1428957.
DOI: 10.1111/j.1365-2125.1976.tb00352.x.
Caddy B, Tilstone W, Johnstone E
Br J Clin Pharmacol. 2012; 3(4):633-7.
PMID: 22216506
PMC: 1428907.
DOI: 10.1111/j.1365-2125.1976.tb04887.x.
Vree T, OREILLY W, Hekster Y, Damsma J, van der Kleijn E
Clin Pharmacokinet. 1980; 5(3):274-94.
PMID: 7389236
DOI: 10.2165/00003088-198005030-00006.
Evans D
J Med Genet. 1984; 21(4):243-53.
PMID: 6387123
PMC: 1049291.
DOI: 10.1136/jmg.21.4.243.
Johnstone E, Marsh W
Proc R Soc Med. 1973; 66(9):947-9.
PMID: 4616245
PMC: 1645414.
Garrod, Galton, and clinical medicine.
Childs B
Yale J Biol Med. 1973; 46(4):297-313.
PMID: 4600783
PMC: 2591916.
A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety.
Tyrer P, Candy J, Kelly D
Psychopharmacologia. 1973; 32(3):237-54.
PMID: 4586902
DOI: 10.1007/BF00422146.
Phenelzine in phobic states.
Kelly D
Proc R Soc Med. 1973; 66(9):949-50.
PMID: 4156084
PMC: 1645420.
Ethnicity and psychopharmacology.
Lin K, Poland R, Lesser I
Cult Med Psychiatry. 1986; 10(2):151-65.
PMID: 2872996
DOI: 10.1007/BF00156581.
N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines.
McKenna K, Baker G, Coutts R
Naunyn Schmiedebergs Arch Pharmacol. 1991; 343(5):478-82.
PMID: 1881457
DOI: 10.1007/BF00169549.
The use of psychotropic drugs: the psychiatrist's view.
Birley J
Br J Clin Pharmacol. 1976; 3(1 Suppl 1):97-8.
PMID: 973953
PMC: 2958711.
DOI: 10.1111/j.1365-2125.1976.tb03722.x.
The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine.
Johnstone E
Psychopharmacologia. 1976; 46(3):289-94.
PMID: 951464
DOI: 10.1007/BF00421116.
The placebo dilemma.
SCHINDEL L
Eur J Clin Pharmacol. 1978; 13(3):231-5.
PMID: 668779
DOI: 10.1007/BF00609988.
Phenelzine: acetylator status and clinical response.
Sanders G, Rawlins M
Br J Clin Pharmacol. 1979; 7(5):451-2.
PMID: 475942
PMC: 1429579.
DOI: 10.1111/j.1365-2125.1979.tb00985.x.
The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial.
Marshall E, Mountjoy C, Campbell I, Garside R, Leitch I, Roth M
Br J Clin Pharmacol. 1978; 6(3):247-54.
PMID: 356868
PMC: 1429446.
DOI: 10.1111/j.1365-2125.1978.tb04593.x.
Some of the problems and difficulties associated with clinical studies of antidepressant agents.
Jenner F
Br J Clin Pharmacol. 1977; 4Suppl 2:199S-207S.
PMID: 334224
PMC: 1429100.
DOI: 10.1111/j.1365-2125.1977.tb05753.x.
Disease and acetylation polymorphism.
Lunde P, Frislid K, Hansteen V
Clin Pharmacokinet. 1977; 2(3):182-97.
PMID: 328206
DOI: 10.2165/00003088-197702030-00003.
Acetylation of phenelzine.
Tilstone W, Margot P, Johnstone E
Psychopharmacology (Berl). 1979; 60(3):261-3.
PMID: 108703
DOI: 10.1007/BF00426665.
